| abstract |
The present invention provides a novel therapeutic anti-Igα-Igβ antibody that binds to an external membrane domain binding region of the Igα-Igβ heterodimer present on the cell surface of B cells. The present invention further contemplates nucleic acid sequences, host cells, and methods of producing the antibody protein. Additionally, pharmaceutical compositions comprising the anti-Igα-Igβ antibody or expression vector encoding the antibody are contemplated. Methods of inducing B cell elimination and treating a condition of inappropriate B cell activity also are contemplated. |